Brief: Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint
26/05/2026 16:24
BRIEF-Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint May 26 (Reuters) - Shanghai Junshi Biosciences Co Ltd 688180.SS:
TORIPALIMAB AS PERIOPERATIVE TREATMENT FOR RESECTABLE STAGE II-III NSCLC- PATIENTS MET PRIMARY ENDPOINT
TORIPALIMAB MET PRIMARY ENDPOINT IN FINAL ANALYSIS OF PHASE III CLINICAL STUDY
Further company coverage: 688180.SS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shanghai Junshi Biosciences Co
See all newsBrief: Shanghai Junshi Biosciences Approved Proposal On Change In Shareholding Structure Of Implementing Entity Of Some Sub-Projects
Brief: Shanghai Junshi Biosciences Says Toripalimab Met Primary Endpoint
Brief: Shanghai Junshi Biosciences Posts Quarterly Net Loss Attributable RMB20.6 Million
Brief: Shanghai Junshi Biosciences Says Shanghai Tanying Plans To Reduce Its Holdings Of Co's Shares
Brief: Shanghai Junshi Biosciences Says From 12 April 2025 To 31 March 2026, Chair Increased Stake